SF 30 P00001.pdf

15BRRC21R00000344/0001 Page 1 of 1

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE PAGE OF PAGES

1 1

2. AMENDMENT/MODIFICATION NUMBER

3. EFFECTIVE DATE

10/28/2021

4. REQUISITION/PURCHASE REQUISITION NUMBER 5. PROJECT NUMBER (If applicable)

CODE

Federal Bureau of Prisons Residential Reentry Contracting 320 First Street, 901-5 Washington, DC 20534

6. ISSUED BY CODE7. ADMINISTERED BY (If other than Item 6)

9A. AMENDMENT OF SOLICITATION NUMBER

15BRRC21R00000344

CODE FACILITY CODE

8. NAME AND ADDRESS OF CONTRACTOR (Number, street, country, state and ZIP Code) (X)

X 9B. DATED (SEE ITEM 11)

09/22/2021

10A. MODIFICATION OF CONTRACT/ORDER

NUMBER

10B. DATED (SEE ITEM 13)

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

X XThe above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended.

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing items 8 and 15, and returning ____copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.

IT MODIFIES THE CONTRACT/ORDER NUMBER AS DESCRIBED IN ITEM 14.

CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT

ORDER NUMBER IN ITEM 10A.

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D. OTHER (Specify type of modification and authority)

E. IMPORTANT: Contractor is not, is required to sign this document and return ____1___ copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

The amendment is to add FAR Clause 52.222.49 Service Contract Labor Standards-Place of Performance Unknown and FAR Deviation Clause 52.223-99 Ensuring Adequate COVID-19 Safety Protocols for Federal Contractors. There are three requirements applicable to FAR Deviation Clause 52.223-99.

1. The "covered contractor employees" must be fully vaccinated by December 8, 2021 and this requirement includes subcontractors.

2. The "covered contractors"should ensure employees follow CDC protocols as described in Safer Federal Workforce Task Force Guidance.

3. The "covered contractors" should designate a lead person for compliance with mandate.

SOW revisions to Chapter 10 Attachments below

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

Melanie Kynard

(Signature of person authorized to sign)

15B. CONTRACTOR/OFFEROR 15C. DATE SIGNED

By (Signature of Contracting Officer)

16B. UNITED STATES OF AMERICA 16C. DATE SIGNED

Previous edition unusable STANDARD FORM 30 (REV. 11/2016) Prescribed by GSA FAR (48 CFR) 53.243

X

10/28/2021

X FAR 43.103 (a) (3)

ATTACHMENT

FAR Deviation Clause

Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors

September 30, 2021

PART 52—SOLICITATION PROVISIONS AND CONTRACT CLAUSES

Subpart 52.2—Text of Provisions and Clauses

[52.223-99 Ensuring Adequate COVID-19 Safety Protocols for Federal Contractors.

ENSURING ADEQUATE COVID-19 SAFETY PROTOCOLS FOR FEDERAL

CONTRACTORS (OCT 2021) (DEVIATION)

(a) Definition. As used in this clause -

United States or its outlying areas means—

(1) The fifty States;

(2) The District of Columbia;

(3) The commonwealths of Puerto Rico and the Northern Mariana Islands;

(4) The territories of American Samoa, Guam, and the United States Virgin Islands;and

(5) The minor outlying islands of Baker Island, Howland Island, Jarvis Island, Johnston Atoll, Kingman Reef, Midway Islands, Navassa Island, Palmyra Atoll, and Wake Atoll.

(b) Authority. This clause implements Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors, dated September 9, 2021 (published in the Federal Register on September 14, 2021, 86 FR 50985).

(c) Compliance. The Contractor shall comply with all guidance, including guidance conveyed through Frequently Asked Questions, as amended during the performance of this contract, for contractor or subcontractor workplace locations published by the Safer Federal Workforce Task Force (Task Force Guidance) at https:/www.saferfederalworkforce.gov/contractors/.

(d) Subcontracts. The Contractor shall include the substance of this clause, including this paragraph (d), in subcontracts at any tier that exceed the simplified acquisition threshold,as defined in Federal Acquisition Regulation 2.101 on the date of subcontract award, and are for services, including construction, performed in whole or in part within the United States or its outlying areas.

(End of clause)]

ATTACHMENT H

Contractor shall conduct specimen validity testing and use an Immunoassay test methodology to screen specimens for the presence of the following drugs at the listed cutoffs:

DRUG SCREEN

Amphetamines(Amphetamine, Methamphetamine) 500 ng/mL MDMA, MDA, MDEA (Ecstasy, Adam, Eve) 500 ng/mL Benzoylecgonine 150 ng/mL Cannabinoids 50 ng/mL Opiates (Morphine, Codeine, Hydromorphone [Dilaudid], Hydrocodone)

300 ng/mL

Oxycodone, Oxymorphone 100 ng/mL

Specimen Validity Testing As part of the screening test panel, individual special tests, and GC/MS confirmation only testing, the contractor shall perform a specimen validity panel to assess the integrity of the specimen provided. This panel shall include tests for specific gravity, pH, and Creatinine. If the specimen shows signs of adulteration by an in-vitro substance other than water, an attempt must be made to identify the adulterant and, if identified, the adulterant shall be reported. When requested, the contractor shall also provide interpretation of the values reported as part of the adulteration panel utilizing PC 1100. The contractor shall report results of the specimen validity panel utilizing the following criteria:

Dilute:

Creatinine equal to or greater than 2 mg/dL and less than or equal to 20 mg/dL (quantitation to one decimal place)

AND/OR

Specific gravity lower than 1.0030 (quantitation to four decimal places) Report as: “Specimen dilute” Substituted:

Creatinine less than 2 mg/dL (quantitation to one decimal place) Report as: “Specimen not consistent with normal human urine.”

Invalid:

Specific gravity equal to or less than 1.0010, or equal to or greater than 1.0450 (quantitation to four decimal places) Report as: “Specimen invalid, not consistent with normal human urine.”

NOTE: The vendor shall only report negative specimens as invalid. Positive specimens that meet the criteria for invalid shall be reported as positive only.

Adulterated:

pH less than 4 or equal to or greater than 10 Report as: “Specimen adulterated, pH is too low (or too high)” Other Adulterants A foreign substance not known to occur in human urine or at a concentration that exceeds normal levels in human urine is identified (e.g., greater than 500 micrograms/mL of nitrites) Report as: “Specimen adulterated, presence of ________ (list the name of substance(s) and/or adulterant(s) detected)”

Drug Testing It is requested all RRC contracts, and IGAs under the RRC Statement of Work be modified to replace the current Attachment H of the Statement of Work, with the revised version of Attachment H (attached). This modification is to correct the language and cut-off levels for urinalysis testing currently used by the BOP. Also, replace the sentence of the SOW which states “Upon approval of the RRM, the contractor may exercise the option of employing alternative methods of testing (e.g., test cup, or strip test) with “The contractor may exercise the option of employing alternative methods of testing (e.g. test cup, or strip test).”

Subsistence Any reference to subsistence collection shall be removed from all RRC and IGA Statement of Work and will no longer be required. Subsistence will not be collected from any resident.

Individualized Program Plan (IPP) Add the following sentence in Chapter 10 – Programs under Individualized Program Plan (IPP): The IPP must be loaded into R3M after every bi-weekly plan update in .pdf format.

If a resident receives a positive test then the contractor shall screen and conduct specimen validity testing for any or all of the following drugs (each shall be requested as an individual drug screen) using the methods and sensitivity listed below:

DRUG SCREEN CUTOFF CONFIRMATION

METHODOLOGY

CUTOFF

d-Lysergic Acid Diethylamide (LSD)

IA < or = 0.5 ng/mL

LC/MS/MS or

GC/MS

< or = 0.5 ng/mL

Anabolic Steroids GC/MS Pos/Neg LC/MS/MS or

GC/MS

Pos/Neg

Ethanol Colormetric 0.2 g/dl GC 0.02% g/dl Barbiturates IA 200 LC/MS/MS or

GC/MS

200 ng/mL

Benzodiazepines IA 200 LC/MS/MS or

GC/MS

200 ng/mL

Methadone IA 200 LC/MS/MS or

GC/MS

300 ng/mL

6-Acetylmorphine

(6-AM)

IA 10 ng/mL LC/MS/MS or

GC/MS

10 ng/mL

Phencyclidine (PCP) IA 25ng/mL LC/MS/MS or

GC/MS

25 ng/mL

Buprenorphine IA 10 LS/MS/MS or

GC/MS

5 ng/mL

Gammahydroxybutyric GC 10 GC 10 ng/mL Ketamine GC/MS 300 LC/MS/MS or

GC/MS

300 ng/mL

Fentanyl IA 2 LC/MS/MS or

GC/MS

0.5 ng/mL

Propoxyphene IA 300 LC/MS/MS or

GC/MS

300 ng/mL

Gabapentin IA 100 ng/mL LC/MS/MS or

GC/MS

100 ng/mL

Tramadol IA 100 ng/mL LC/MS/MS or

GC/MS

100 ng/mL

Mitragynine (Kratom)

IA 25 ng/mL LC/MS/MS or

GC/MS

25 ng/mL

Synthetic Stimulants

IA 25 ng/mL LC/MS/MS or

GC/MS

25 ng/mL

Synthetic Cannanbinoids

IA 25 ng/mL LC/MS/MS or

GC/MS

1 ng/mL